Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Stopped early · Phase 1
Conditions studied: Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma
In brief
This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma
Key facts
- Study ID
- NCT05166577
- Run by
- Viracta Therapeutics, Inc.
- People needed
- 26
- Starts
- 2021-10-08
- Expected to finish
- 2025-01-10
- Last updated by the study team
- 2025-03-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford Cancer Center — Stanford, California, United States
- University of Colorado Hospital — Aurora, Colorado, United States
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Blacktown Hospital — Blacktown, Australia
- Princess Margaret Cancer Centre — Toronto, Canada
- Queen Mary Hospital — Hong Kong, Hong Kong
- Prince Of Wales Hospital, The Chinese University Of Hong Kong — Shatin, Hong Kong
- Sarawak General Hospital — Kuching, Sarawak, Malaysia
- University of Malaya Medical Centre — Kuala Lumpur, Malaysia
- National Cancer Centre Singapore — Singapore, Singapore
- Samsung Medical Center — Seoul, South Korea
- Taipei Veterans General Hospital — Taipei, Taiwan
- Linkou Chang Gung Memorial Hospital — Taoyuan City, Taiwan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.